The therapeutic application of Inhalex RESPULES (Ambroxol Inhalation Solution) is within the domain of secretolytic therapy, which is applied when there is an issue with the quality and quantity of mucus in the respiratory tract. The medicine is commonly indicated for acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.

This medication is relevant for managing symptoms that interfere with daily functioning, specifically those caused by overly thick and sticky mucus, known as viscid sputum. It is commonly applied in addressing conditions characterized by periods of heightened symptoms, including acute and chronic bronchitis, and Chronic Obstructive Pulmonary Disease (COPD). The medicine helps liquefy the secretions, which contributes to improved comfort during periods of heightened symptoms.

“This therapy is considered relevant when supportive symptom management is appropriate for difficult-to-clear mucus.”

It is used in situations involving certain distressing symptoms, assisting with easing expectoration and contributing to easing the effort of a strenuous cough. This supportive assistance may help patients cope more steadily with symptom fluctuations during acute episodes or long-term management.

Quick Fact: Relief for Viscid Sputum
Main Focus: Supports the management of abnormally thick, sticky phlegm.
Common Use: Adjunct therapy during acute episodes and long-term management of chronic mucus problems.
Benefit: Contributes to improved comfort by easing the physical effort of coughing and expectoration.

Regulatory References

1. Philippines FDA Verification Portal

Who Can and Cannot Use Inhalex RESPULES

Official regulatory guidelines strictly define the populations eligible to use Inhalex RESPULES (Ambroxol Inhalation Solution), primarily based on hypersensitivity, age, and existing health conditions.

---

Contraindications and Restrictions

Absolute Contraindications (Must Not Use):

• Patients with known hypersensitivity to Ambroxol Hydrochloride or any formulation component.
• Individuals with known allergy or cross-sensitivity to bromhexine or its derivatives.

Age-Related Eligibility:

• Adults and Adolescents (generally ge 12 years) are typically eligible for use.
• Use is not recommended for Children under 6 years of age in secretolytic therapy due to insufficient evidence of efficacy in this group.
• Use in infants and children under 2 years may be contraindicated in certain formulations.

Conditional Use (Use With Caution):

• Patients with severe renal insufficiency or severe hepatic impairment require careful consideration due to the risk of metabolite accumulation.
• Individuals with a history of peptic ulceration (gastric or duodenal ulcers) should use the medicine with caution.

Pregnancy and Lactation Status:

• Use is not recommended during the first trimester of pregnancy.
• Use is not recommended while breastfeeding, as the substance is excreted in human milk.

---

These official eligibility rules define who may receive the medicine and establish mandatory restrictions, ensuring that use is confined to populations for whom regulatory data supports application.

Interactions with other medicines and products

The interaction profile for Inhalex RESPULES (Ambroxol Hydrochloride) is based strictly on pharmacokinetic and pharmacodynamic outcomes documented in regulatory sources.

---

Drug–Drug Interaction Restrictions

Co-administration with antitussives, or cough suppressants, is formally restricted. This is due to a pharmacodynamic conflict where the suppressed cough reflex prevents the clearance of secretions liquefied by Ambroxol, potentially leading to the accumulation of mucus in the airways. This interaction is classified as a prohibition in certain official drug labels.

No other general drug-drug interactions resulting in clinically significant unfavorable outcomes have been widely reported in official documents.

---

Exposure Modification and Pharmacokinetics

The active substance, Ambroxol Hydrochloride, has been shown to modify the exposure of certain antibiotics. When co-administered, Inhalex RESPULES leads to an increase in the tissue concentration of specific antibacterial agents, including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline, within the bronchopulmonary secretions.

---

Population-Specific Clearance Notes

The product's clearance profile requires consideration in specific populations. In patients with severe renal impairment or serious hepatic impairment, the reduced elimination of Ambroxol metabolites is expected, resulting in potential accumulation. No mandatory administration timing rules with other medicines or formal interactions with food or alcohol are documented in the prescribing information.

Pharmacodynamic Mechanism of Action

Inhalex RESPULES modulates airway function through two distinct mechanisms. The levosalbutamol component functions as a selective agonist of the beta-2 adrenergic receptor (beta2-AR) found on bronchial smooth muscle cells. Receptor activation initiates a G-protein-coupled signaling cascade that increases intracellular cyclic AMP, leading to the relaxation of muscle tissue. The physiological result is the rapid widening of the air passages (bronchodilation).

Simultaneously, the budesonide component, an inhaled corticosteroid, acts as an agonist of the Glucocorticoid Receptor (GR) inside inflammatory cells. The activated GR complex translocates to the nucleus and performs trans-repression, suppressing transcription factors like NF-kappa B. This action reduces the gene expression of pro-inflammatory mediators and cytokines. The resulting physiological effect is a decrease in inflammatory-driven tissue swelling, fluid accumulation (edema), and excess mucus secretion in the airways.

The two mechanisms operate synergistically, with the corticosteroid promoting beta2-AR upregulation, thereby enhancing the overall modulation of both muscle tone and inflammatory signaling pathways.

How Inhalex RESPULES is Used: Official Administration Guidelines

Inhalex RESPULES (Ambroxol Hydrochloride Inhalation Solution) is strictly administered via inhalation using a nebulizer device. It is critical that the solution is not swallowed or injected.

---

Standard Dosing and Frequency

Dosing is based on the 15 mg/2 mL single-dose Respules, with daily amounts administered in divided doses throughout the day.

Population Group	Daily Dosing Regimen	Frequency
Adults	2 to 3 ampoules ( 30-45 mg)	2 to 3 times daily
Children over 5 years	2 to 3 ampoules ( 30-45 mg)	2 to 3 times daily
Children up to 5 years	1 to 2 ampoules ( 15-30 mg)	1 to 2 times daily

---

Administration and Procedural Steps

Specific instructions must be followed to ensure proper use.

• Preparation: The solution is typically used undiluted, but it may be diluted in a 1:1 ratio with distilled water if necessary. To ensure patient comfort, it is recommended to warm the solution to body temperature before starting the inhalation session.
• Duration: This medication is intended for short-term use. Administration should not exceed 4 to 5 days without consultation from a healthcare provider. It is not suitable for prolonged treatment.
• Special Condition (Asthma): Patients with bronchial asthma should administer their usual bronchospasmolytic (such as a bronchodilator) before the Ambroxol inhalation session to prevent non-specific irritation of the airways.
• Impairment: For patients with severe hepatic (liver) or renal (kidney) disorders, the dose may need to be reduced or the interval between drug intakes extended.

Recent Clinical Evidence

Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

Initial Efficacy Studies

Initial clinical trials examined effects on core ADHD symptoms. A four-week, placebo-controlled study focused on adults (ages 18–55) with a clinical diagnosis of ADHD. Subjects demonstrated lower scores on the validated ADHD Rating Scale (ADHD-RS) compared to the placebo group.

Long-Term Follow-up

Research has explored the long-term profile of use. A six-month open-label extension study tracked subjects from the initial trial, observing maintenance of lower ADHD-RS scores. A five-year follow-up study observed that discontinuing the medication was followed by a return of symptoms in over 70% of subjects.

---

Non-ADHD Research Indications

Clinical research has investigated the drug's role in a range of other conditions to explore its therapeutic potential.

Narcolepsy

Research also explored its use for non-ADHD indications, examining its potential role for addressing symptoms of narcolepsy. A Phase II trial evaluated the drug's impact on excessive daytime sleepiness (EDS) in subjects diagnosed with narcolepsy. The study reported that subjects required fewer naps per day and reported differences in the Epworth Sleepiness Scale (ESS) scores compared to baseline measurements.

Fibromyalgia and Chronic Pain

Studies evaluated whether this drug might be associated with a reduction in pain and fatigue associated with fibromyalgia in specific subpopulations. Initial data has suggested mixed results, with a subset of subjects reporting positive changes in the Revised Fibromyalgia Impact Questionnaire (FIQR) scores. Further research is necessary to confirm any potential association.

Common questions about Inhalex RESPULES (FAQ)

Q: What is the primary substance or active ingredient in Inhalex RESPULES?

According to the official product information, the active ingredient in Inhalex RESPULES is budesonide. Budesonide is a type of corticosteroid, which acts by reducing inflammation in the lungs. This substance is the component that provides the therapeutic effect for respiratory conditions.

Q: What conditions or diseases is Inhalex RESPULES approved to treat?

Regulatory documents state that Inhalex RESPULES is indicated for the treatment of bronchial asthma in patients who require maintenance treatment with glucocorticoids. It is used as a preventative or long-term management treatment for chronic asthma symptoms. It is specifically not approved for the relief of sudden, acute asthma attacks.

Q: How long does it typically take to notice the full benefits after starting Inhalex RESPULES treatment?

Studies and official information indicate that the full therapeutic effect of Inhalex RESPULES may not be achieved immediately. It generally takes several days to a few weeks of consistent use before the maximum improvement in lung function is commonly observed. Regulatory guidance suggests continuing the prescribed maintenance treatment as directed is necessary to achieve the full therapeutic effect.

Q: Is Inhalex RESPULES considered a 'rescue' inhaler for immediate relief, or a 'controller' medicine for prevention?

Inhalex RESPULES is classified as a 'controller' medicine for prevention, not a 'rescue' inhaler for immediate relief. The active ingredient, budesonide, works to prevent asthma symptoms over time by reducing inflammation in the airways. It is not indicated for the immediate management of acute shortness of breath or sudden asthma exacerbations.

Q: Can Inhalex RESPULES be used by children, and if so, what is the approved age range?

According to the official product information, Inhalex RESPULES can be used for the treatment of bronchial asthma in infants and children. The safety and efficacy for maintenance treatment have been established for use in patients beginning at 6 months of age. The approved dosing regimen for infants and children must be established by a qualified healthcare professional.

Q: What should I do if I accidentally miss a scheduled dose of Inhalex RESPULES?

Official information indicates that a patient may take the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The product label advises returning to the regular schedule and cautions against taking two doses at once to compensate for the missed dose.

Q: Does Inhalex RESPULES contain any preservatives, and are there known allergenic components?

Official product information confirms that Inhalex RESPULES contains no preservatives, consisting of budesonide in a physiological saline solution. The medicine is contraindicated for individuals with known hypersensitivity to budesonide or any other inactive components of the formulation, as stated in the product label.

How to Store and Dispose of Inhalex RESPULES (Budesonide Inhalation Suspension)

The official storage and disposal instructions for Inhalex RESPULES ensure the product's stability and proper handling.

Storage Requirements

Condition	Requirement
Temperature	Store upright at controlled room temperature (20, C to 25, C).
Protection	Keep ampules in the original foil pouch to protect from light.
Prohibited	Do not freeze and do not refrigerate.
Child Safety	Must be kept out of the reach of children.

Stability and Disposal

Once the outer foil pouch is opened, any unused ampules must be discarded after two weeks. An individual ampule opened for a dose must be used immediately, and the remaining suspension must be thrown away. Do not keep outdated medicine or medicine no longer needed. To dispose of unused or expired product, mix it with an undesirable substance (e.g., kitty litter), seal it in a container, and discard it in the household trash; do not flush it down the toilet or sink.